Bleeding and thrombosis in acute promyelocytic leukemia

摘要: Acute promyelocytic leukemia (APL) has evolved from being a deadly to highly curable disease, due targeted molecular therapy with all-trans retinoic acid (ATRA). As result, the incidence of early hemorrhagic deaths for which APL is notorious reduced 5-10% as reported in clinical trials. These results are not replicated outside trials evident recent population-based registries. High remains greatest contributor treatment failure this otherwise leukemia. Additionally, thrombosis now increasingly recognized patients and may be associated ATRA usage.